Purpose: Guidelines from the NCCN Ò (National Comprehensive Cancer NetworkÒ) advocate digital rectal examination screening only in men with elevated prostate specific antigen. We investigated the effect of prostate specific antigen on the association of digital rectal examination and clinically significant prostate cancer in a large American cohort. Materials and Methods: We evaluated the records of the 35,350 men who underwent digital rectal examination in the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening trial for the development of clinically significant prostate cancer (Gleason 7 or greater). Followup was 343,273 person-years. The primary outcome was the rate of clinically significant prostate cancer among men with vs without suspicious digital rectal examination. We performed competing risks regression to evaluate the interaction between time varying suspicious digital rectal examination and prostate specific antigen.
THE landscape of prostate cancer screening and diagnosis in the United States has evolved dramatically in the last decade. These changes have led to reverse stage migration in prostate cancer as patients now present with higher grade and stage disease. 1, 2 In this setting researchers and policy makers have reevaluated the role of screening and methods of implementation to alter the epidemiological trends toward higher risk disease.
One aspect of prostate cancer screening that remains unsettled is the role of DRE. DRE was the fundamental component of prostate cancer screening regimens prior to widespread dissemination of PSA. 3 By the 1990s regimens consisting of DRE and PSA were often used and prostate biopsy was recommended if either was abnormal. 4 However, concerns regarding the insensitivity of DRE for screening were ultimately recognized in ERSPC, in which DRE was abandoned as a primary screening tool due to its inefficiency to detect cancer during the initial stages of the trial. 5, 6 Subsequent ERSPC data revealed that abnormal DRE was associated with prostate cancer in the setting of elevated PSA and yet the role of DRE in the setting of normal PSA remained under studied. 7, 8 This is reflected in the conflicting guidelines regarding DRE use. The AUA (American Urological Association) found no evidence in support of DRE 9 while NCCN advocated DRE screening only in men with elevated PSA. 10 We recently reported that DRE was associated with the detection of CSPC independent of PSA levels.
11 Given this finding, 2 distinct roles for DRE are possible in prostate cancer screening protocols, including as 1) a primary screening test to improve the sensitivity of PSA or 2) a reflex test to improve its specificity. To determine whether either, neither or both of these approaches are clinically useful we investigated the effect of serum PSA levels on the association between DRE and subsequent detection of CSPC in a large, nationally representative cohort.
METHODS

Data Source and Study Population
We analyzed the records of all 35,350 men who underwent DRE as part of the screening protocol of the PLCO Cancer Screening Trial. The PLCO trial is a multiinstitutional, randomized controlled trial of prostate cancer screening that has been described previously. 12 Briefly, from 1993 through 2001 men 55 to 74 years old were randomized to routine prostate cancer screening with DRE and PSA or to usual care. Men in the screening arm underwent annual DRE and PSA testing for the first 4 and 6 years of the trial, respectively. Because information on DRE in men in the usual care arm was not recorded as part of the trial, these men were excluded from the current analysis.
Following a positive screening test (elevated PSA or positive DRE) the subsequent diagnostic and therapeutic course of each man was determined by his individual physician. Followup was available for 13 years after trial initiation, throughout which study coordinators actively tracked trial participant screening test results, medical records, diagnostic evaluations, treatments and oncologic end points.
Study Variables
The primary independent variable was the presence or absence of suspicious abnormality on DRE performed by the screening clinician (physician, physician assistant or nurse). 13 DRE was considered positive or suspicious in the presence of induration, nodularity, significant asymmetry or loss of anatomical landmarks as determined by the examiner. 12 Quality assurance protocols were used to select certain men for repeat DRE by an independent examiner at the same screening encounter. In the event of discordant results an individualized screening outcome and diagnostic course were determined for each patient. Examiners were blinded to PSA results as blood draws were typically performed before and within a 2-hour window of examination. 12 Our primary end point was the detection of CSPC, defined as Gleason score 7 or greater and Gleason Grade Group 2 or greater. Gleason score was determined using the highest pathological grade of all tissue samples for each subject with 54% and 46% of Gleason scores resulting from biopsy and radical prostatectomy, respectively.
DRE is an indication for biopsy, raising the possibility of verification bias. Two factors mitigated against this being a strong effect in the current study. 1) Men with positive DRE and negative PSA had a biopsy rate of only 27% within 3 years of the examination, suggesting that DRE was not a strong indication for biopsy. 13 2) Our study end point of CSPC is less subject to verification bias because it is less prone to over diagnosis.
Statistical Analysis
We performed age adjusted, competing risks regression analysis to evaluate the relationship of DRE and PSA with the detection of CSPC using Fine and Gray models. 14 Ever suspicious DRE and highest PSA to date were considered time varying variables across all 4 screening encounters for each patient.
Patients were categorized throughout followup according to the latest DRE and PSA status. At the time of the first screening patients were categorized by the result of the DRE screening and those with suspicious DRE remained in this category for the duration of followup. If and when a patient with an initially nonsuspicious DRE had a suspicious finding, he was transferred to the suspicious group for the remainder of the study. If a patient who had not had a suspicious DRE missed a screening, he was removed from analysis until the following screening. Similarly for PSA a patient was categorized by the initial PSA level and if a subsequent PSA value was higher, he was moved to a new category. After the fourth screening patients remained in the same category throughout followup.
The cumulative incidence of CSPC was characterized in patients according to DRE status and stratified by PSA level into 3 groups, including normaldPSA less than 2 ng/ ml, equivocald2 ng/ml or greater and less than 3 ng/ml, and elevatedd3 ng/ml or greater. Using these models stratified by PSA levels cumulative incidence curves were constructed and the 10-year relative risk of CSPC for suspicious DRE was determined.
Statistical analyses were performed using R, version 3.2.3 (https://www.r-project.org/). Analyses were 2-sided with significance considered at 0.05 and CIs presented at the 95% level. Bootstrapping methods were used to determine the CIs of model based estimates.
RESULTS
With a followup of 343,273 person-years a total of 1,713 CSPCs were detected in 35,350 men (table 1) . The overall 10-year cumulative incidence of CSPC was 5.9% (95% CI 5.6e6.2). As previously reported, 11 suspicious DRE and higher PSA were associated with a higher risk of CSPC. There was a statistically significant interaction between PSA and DRE. Suspicious DRE was associated with a smaller increase in the relative risk of CSPC in men with higher PSA compared to those with lower PSA (p <0.001).
The 10-year cumulative incidence of CSPC was higher in men with suspicious vs nonsuspicious DRE across all PSA level categories ( fig. 1) . When stratified by PSA group, the cumulative incidence of CSPC remained higher among patients with suspicious vs nonsuspicious DRE across all PSA groups (all analyses p <0.001, table 2 and fig. 2 ), including the normal (1.5% vs 0.73%), equivocal (6.5% vs 3.5%) and elevated gropus (23% vs 14%). In relative terms there was a 2.1-fold (95% CI 1.7e2.4), 1.9-fold (95% CI 1.5e2.2) and 1.7-fold (95% CI 1.6e1.8) increase in the cumulative incidence of CSPC when comparing men with suspicious to those with nonsuspicious DRE across the 3 PSA groups, respectively. In absolute terms suspicious DRE was associated with 0.8% (bootstrap 95% CI 0.4e1.0), 3.0% (95% CI 1.9e4.0) and 9.3% (95% CI 7.8e10) absolute increases in the cumulative incidence of CSPC across the 3 PSA groups, respectively. Subgroup analysis stratified by pathology source (biopsy only or prostatectomy) and in African American men showed similar trends (supplementary tables 1 to 3, http://jurology.com/).
DISCUSSION
DRE was the fundamental component of prostate cancer screening regimens during the initial wave of population based screening in the 1980s. 3 With widespread dissemination of PSA testing in subsequent decades the national discourse regarding prostate cancer screening has been dominated by PSA, culminating with the results and controversy surrounding the PLCO Cancer Screening Trial. 15, 16 Because researchers and policy makers have focused on optimizing PSA for screening, the role of DRE has remained largely under studied. As mentioned, the 2013 AUA guideline on the early detection of prostate cancer suggested that DRE may be useful as an adjunct to PSA to determine the need for prostate biopsy but sufficient evidence was lacking. 9 In contrast, the 2016 NCCN Guidelines Ò recommended DRE use but only in men with elevated PSA while also noting that DRE may be considered a baseline test in all patients due to the ability to detect high grade cancer in the absence of elevated PSA. 10 Given the lack of consensus regarding the usefulness of DRE for prostate cancer screening, we evaluated the relationship between PSA and DRE in a large, multi-institutional cohort from the PLCO trial. Our study has a number of important findings. 1) Suspicious DRE was associated with a higher risk of CSPC across all PSA levels. Prior randomized trials demonstrated correlations between abnormal DRE and CSPC, although these studies generally did not investigate the interaction between DRE and PSA. 8, 17, 18 Cui et al also reported a relationship of DRE and PSA with CSPC in the PLCO trial, although competing risks were not considered and the interaction of DRE and PSA was not evaluated. 19 The current study expands on these data in demonstrating an elevated risk of CSPC among men with suspicious DRE across all PSA categories.
2) Suspicious DRE was associated with a significantly increased relative and absolute risk of CSPC among men with elevated PSA (3 ng/ml or greater). Men presenting with elevated PSA and suspicious DRE had a 9% higher cumulative incidence of CSPC compared to those with nonsuspicious DRE. This risk increase is consistent with findings from Gosselaar et al that men in ERSPC with abnormal DRE and PSA 3 ng/ml or greater were at increased risk for CSPC compared to those with normal DRE (positive predictive value 49% vs 22%). 8 Given this substantial risk difference, DRE can improve clinical decision making for men with elevated PSA who are unsure whether to pursue prostate biopsy.
3) DRE had less clinical value in men with normal or equivocal PSA, in whom the absolute risk of CSPC is low. To date the role of DRE in this subgroup of patients has been unclear in the era of PSA screening. ERSPC was initially designed to examine the usefulness of DRE in the setting of normal PSA. 5 However, a change in study protocol based on preliminary data led to the avoidance of DRE (and prostate biopsy) in men with PSA less than 3 ng/ml. In the PLCO trial we found that the relative risk of CSPC in men with nonelevated (normal or equivocal) PSA and suspicious DRE was 1.9-fold to 2.1-fold greater than in the men with nonsuspicious DRE. However, the absolute risk difference between these groups was minor at merely 1% and 3%, respectively. While statistically significant, this difference is unlikely to influence clinical decision making.
The current study supports and expands on previously published results from PCPT (Prostate Cancer Prevention Trial). 20, 21 These data showed that the absolute risk of high grade cancer associated with positive DRE is higher as PSA increases. For example, a 65-year-old Caucasian male with no prior biopsy, PSA 2 ng/ml and negative vs positive DRE is at 3% vs 5% risk for high grade cancer on biopsy, which translates to a 2% absolute risk increase for positive DRE. However, the same patient with higher PSA 4 ng/ml and negative vs positive DRE is at 6% vs 9% risk for high grade cancer on biopsy, which translates to a 3% absolute risk increase for DRE. Our findings expand these data by demonstrating that differences in the absolute risk associated with DRE persist beyond the immediate biopsy result and translate to a long-term prognosis for the development of high risk cancer.
Our findings along with historical data reaffirm the NCCN Guidelines, 10 suggesting that DRE may be best used as a followup and an adjunct test in men with elevated PSA. Based on these data we recommend that screening be performed in 2 separate stages. 1) Primary care physicians would draw blood for PSA assays in men who have elected PSA Our results must be interpreted in the context of the study design. 1) We evaluated all screening encounters in aggregate to assess DRE and PSA as time varying variables. However, this precluded any distinction between the prognostic significance of initial vs subsequent DRE, which has been previously demonstrated. 8 2) DRE in the PLCO trial was performed by physicians or screening clinicians (physician assistants or nurses) who were trained and supervised by a licensed physician, typically a urologist. 13, 22 To our knowledge it is unknown how the reproducibility and sensitivity of DRE performed by community urologists compares to use in the PLCO.
3) Detection of CSPC in the PLCO trial was confounded by the biopsy rate since no standard protocol for biopsy performance existed in the trial. 13 As noted previously, the 27% biopsy rate among men with positive DRE and normal PSA in the trial is protective against verification bias in the current study. With that said, this low biopsy rate may have also resulted in under detection of CSPC in this cohort, thereby underestimating the clinical usefulness of DRE in men with normal PSA. 4) Due to the age restrictions of men in the PLCO trial 13 our data may not be generalizable to younger men who pursue screening. In these men alternate PSA cutoffs may be appropriate and the role of DRE must be further refined.
CONCLUSIONS
In this retrospective analysis of data from the PLCO trial suspicious DRE was significantly associated with CSPC across all PSA levels. DRE demonstrated substantial prognostic usefulness for PSA greater than 3 ng/ml, limited clinical usefulness when PSA was less than 2 and some benefit in the setting of equivocal PSA 2 to 3 ng/ml. These findings provide support for the NCCN Guidelines recommendation to restrict DRE to men with higher PSA as a followup test to improve specificity. 10 DRE should not be used as a primary screening modality. Further research is warranted on the value of DRE in men with equivocal PSA 2 to 3 ng/ml.
